nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-6-122-127nnp-2148Research ArticleREVIEWSОБЗОРЫ«Gut-brain» axis and multiple sclerosisОсь «кишечник – мозг» и рассеянный склероз (обзор)https://orcid.org/0000-0002-6744-2191ОмароваМ. А.OmarovaM. A.

Мадина Алиевна Омарова - Кафедра неврологии, нейрохирургии и медицинской генетики.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10

Madina Alievna Omarova - Department of Neurology, Neurosurgery and Medical Genetics.

11, Ostrovityanova St., Moscow 117997; 1, Ostrovityanova St., Build. 10, Moscow 117997

omarova.neurology@mail.ruhttps://orcid.org/0000-0002-2975-4151БойкоА. Н.BoykoA. N.

Кафедра неврологии, нейрохирургии и медицинской генетики.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10

Department of Neurology, Neurosurgery and Medical Genetics.

11, Ostrovityanova St., Moscow 117997; 1, Ostrovityanova St., Build. 10, Moscow 117997

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of RussiaRussian Federation202317122023156122127Copyright © Omarova M.A., Boyko A.N., 20232023Омарова М.А., Бойко А.Н.Omarova M.A., Boyko A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2148

An increase in the incidence of multiple sclerosis (MS) has been reported over the last decade, possibly due to environmental factors. The purpose of this review article is to summarize current advances in the understanding of the gut-brain axis, which mediates the link between the central nervous system and the gut microbiome. It also summarizes the clinical findings from numerous studies investigating the effects of diseasemodifying therapies on the gut microbiome in patients with MS.

За последнее десятилетие сообщается о росте заболеваемости рассеянным склерозом (РС), и это может быть связано с факторами окружающей среды. Целью этой обзорной статьи является обобщение текущих достижений, направленных на изучение оси «кишечник – мозг», которая обеспечивает связь между центральной нервной системой и микробиомом кишечника. Также резюмируются клинические данные, полученные в результате многих исследований, в которых оценивалось влияние терапии, изменяющей течение заболевания, на микробиом кишечника у пациентов с РС.

микробиом кишечникаось «кишечник – мозг»метагеномикарассеянный склерозтерапияизменяющая течение рассеянного склерозаgut microbiomegut-brain axismetagenomicsmultiple sclerosistherapydisease modifying therapy for multiple sclerosisИсследование было выполнено при финансовой поддержке РФН, грант № 22-15-00284. Исследование не имело спонсорской поддержкиThe study was supported by Russian Science Foundation grant No. 22-15-00284. The investigation has not been sponsoredReferencesGBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38.Grytten N, Torkildsen O, Myhr KM. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurol Scand. 2015;132(199):29-36. doi: 10.1111/ane.12428Grytten N, Torkildsen O, Myhr KM. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurol Scand. 2015;132(199):29-36. doi: 10.1111/ane.12428Filippi M, Rocca MA, Ciccarelli O, et al; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S14744422(15)00393-2. Epub 2016 Jan 26.Filippi M, Rocca MA, Ciccarelli O, et al; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S14744422(15)00393-2. Epub 2016 Jan 26.Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019 Jan;15(1):53-8. doi: 10.1038/s41582-018-0082-zTintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019 Jan;15(1):53-8. doi: 10.1038/s41582-018-0082-zHenze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105. doi: 10.1159/000095699. Epub 2006 Sep 8.Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105. doi: 10.1159/000095699. Epub 2006 Sep 8.Glaser A, Stahmann A, Meissner T, et al. Multiple sclerosis registries in Europe – An updated mapping survey. Mult Scler Relat Disord. 2019 Jan;27:171-8. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4.Glaser A, Stahmann A, Meissner T, et al. Multiple sclerosis registries in Europe – An updated mapping survey. Mult Scler Relat Disord. 2019 Jan;27:171-8. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4.McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatriconset multiple sclerosis. Neurology. 2019 Jun 11;92(24):e2764-e2773. doi: 10.1212/WNL.0000000000007647. Epub 2019 May 15.McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatriconset multiple sclerosis. Neurology. 2019 Jun 11;92(24):e2764-e2773. doi: 10.1212/WNL.0000000000007647. Epub 2019 May 15.Guillemin F, Baumann C, Epstein J, et al; LORSEP Group. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study. Neuroepidemiology. 2017;48(3-4):179-87. doi: 10.1159/000479516. Epub 2017 Aug 10.Guillemin F, Baumann C, Epstein J, et al; LORSEP Group. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study. Neuroepidemiology. 2017;48(3-4):179-87. doi: 10.1159/000479516. Epub 2017 Aug 10.Patsopoulos NA. Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):a028951. doi: 10.1101/cshperspect.a028951Patsopoulos NA. Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):a028951. doi: 10.1101/cshperspect.a028951Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015 Mar;14(3):263-73. doi: 10.1016/S14744422(14)70267-4. Epub 2015 Feb 4.Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015 Mar;14(3):263-73. doi: 10.1016/S14744422(14)70267-4. Epub 2015 Feb 4.Zheng C, He L, Liu L, et al. The efficacy of vitamin D in multiple sclerosis: A metaanalysis. Mult Scler Relat Disord. 2018 Jul;23:56-61. doi: 10.1016/j.msard.2018.05.008. Epub 2018 May 12.Zheng C, He L, Liu L, et al. The efficacy of vitamin D in multiple sclerosis: A metaanalysis. Mult Scler Relat Disord. 2018 Jul;23:56-61. doi: 10.1016/j.msard.2018.05.008. Epub 2018 May 12.Camara-Lemarroy CR, Metz LM, Yong VW. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome. World J Gastroenterol. 2018 Oct 7;24(37):4217-23. doi: 10.3748/wjg.v24.i37.4217Camara-Lemarroy CR, Metz LM, Yong VW. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome. World J Gastroenterol. 2018 Oct 7;24(37):4217-23. doi: 10.3748/wjg.v24.i37.4217Pröbstel AK, Baranzini SE. The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the “MS Microbiome”. Neurotherapeutics. 2018 Jan;15(1):126-34. doi: 10.1007/s13311-017-0587-yPröbstel AK, Baranzini SE. The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the “MS Microbiome”. Neurotherapeutics. 2018 Jan;15(1):126-34. doi: 10.1007/s13311-017-0587-yLahiri DK, Maloney B. The “LEARn” (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol. 2010 Apr;45(4):291-6. doi: 10.1016/j.exger.2010.01.001. Epub 2010 Jan 11.Lahiri DK, Maloney B. The “LEARn” (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol. 2010 Apr;45(4):291-6. doi: 10.1016/j.exger.2010.01.001. Epub 2010 Jan 11.Xia Z, Steele SU, Bakshi A, et al. Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members. JAMA Neurol. 2017 Mar 1;74(3):293-300. doi: 10.1001/jamaneurol.2016.5056Xia Z, Steele SU, Bakshi A, et al. Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members. JAMA Neurol. 2017 Mar 1;74(3):293-300. doi: 10.1001/jamaneurol.2016.5056Freedman SN, Shahi SK, Mangalam AK. The “Gut Feeling”: Breaking Down the Role of Gut Microbiome in Multiple Sclerosis. Neurotherapeutics. 2018 Jan;15(1):109-25. doi: 10.1007/s13311-017-0588-xFreedman SN, Shahi SK, Mangalam AK. The “Gut Feeling”: Breaking Down the Role of Gut Microbiome in Multiple Sclerosis. Neurotherapeutics. 2018 Jan;15(1):109-25. doi: 10.1007/s13311-017-0588-xPicca A, Fanelli F, Calvani R, et al. Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia. Mediators Inflamm. 2018 Jan 30;2018:7026198. doi: 10.1155/2018/7026198Picca A, Fanelli F, Calvani R, et al. Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia. Mediators Inflamm. 2018 Jan 30;2018:7026198. doi: 10.1155/2018/7026198Ochoa-Reparaz J, Magori K, Kasper LH. The chicken or the egg dilemma: intestinal dysbiosis in multiple sclerosis. Ann Transl Med. 2017 Mar;5(6):145. doi: 10.21037/atm.2017.01.18Ochoa-Reparaz J, Magori K, Kasper LH. The chicken or the egg dilemma: intestinal dysbiosis in multiple sclerosis. Ann Transl Med. 2017 Mar;5(6):145. doi: 10.21037/atm.2017.01.18Blum HE. The human microbiome. Adv Med Sci. 2017 Sep;62(2):414-20. doi: 10.1016/j.advms.2017.04.005. Epub 2017 Jul 13.Blum HE. The human microbiome. Adv Med Sci. 2017 Sep;62(2):414-20. doi: 10.1016/j.advms.2017.04.005. Epub 2017 Jul 13.Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014 Oct;14(10):667-85. doi: 10.1038/nri3738. Epub 2014 Sep 19.Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014 Oct;14(10):667-85. doi: 10.1038/nri3738. Epub 2014 Sep 19.Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther. 2016 Feb;158:52-62. doi: 10.1016/j.pharmthera.2015.11.012. Epub 2015 Nov 26.Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther. 2016 Feb;158:52-62. doi: 10.1016/j.pharmthera.2015.11.012. Epub 2015 Nov 26.Fleck AK, Schuppan D, Wiendl H, Klotz L. Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis. Int J Mol Sci. 2017 Jul 14;18(7):1526. doi: 10.3390/ijms18071526Fleck AK, Schuppan D, Wiendl H, Klotz L. Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis. Int J Mol Sci. 2017 Jul 14;18(7):1526. doi: 10.3390/ijms18071526Vatanen T, Kostic AD, d'Hennezel E, et al; DIABIMMUNE Study Group; Xavier RJ. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016 May 5;165(4):842-53. doi: 10.1016/j.cell.2016.04.007. Epub 2016 Apr 28. Erratum in: Cell. 2016 Jun 2;165(6):1551.Vatanen T, Kostic AD, d'Hennezel E, et al; DIABIMMUNE Study Group; Xavier RJ. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016 May 5;165(4):842-53. doi: 10.1016/j.cell.2016.04.007. Epub 2016 Apr 28. Erratum in: Cell. 2016 Jun 2;165(6):1551.Frantz AL, Rogier EW, Weber CR, et al. Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin2, and antibacterial peptides. Mucosal Immunol. 2012 Sep;5(5):501-12. doi: 10.1038/mi.2012.23. Epub 2012 Apr 11.Frantz AL, Rogier EW, Weber CR, et al. Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin2, and antibacterial peptides. Mucosal Immunol. 2012 Sep;5(5):501-12. doi: 10.1038/mi.2012.23. Epub 2012 Apr 11.Nieuwenhuis EE, Matsumoto T, Lindenbergh D, et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest. 2009 May;119(5):124150. doi: 10.1172/JCI36509. Epub 2009 Apr 6.Nieuwenhuis EE, Matsumoto T, Lindenbergh D, et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest. 2009 May;119(5):124150. doi: 10.1172/JCI36509. Epub 2009 Apr 6.Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1981-6. doi: 10.1073/pnas.0307317101. Epub 2004 Feb 6.Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1981-6. doi: 10.1073/pnas.0307317101. Epub 2004 Feb 6.Hapfelmeier S, Lawson MA, Slack E, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010 Jun 25;328(5986):17059. doi: 10.1126/science.1188454Hapfelmeier S, Lawson MA, Slack E, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010 Jun 25;328(5986):17059. doi: 10.1126/science.1188454Dias J, Leeansyah E, Sandberg JK. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):E5434E5443. doi: 10.1073/pnas.1705759114. Epub 2017 Jun 19.Dias J, Leeansyah E, Sandberg JK. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):E5434E5443. doi: 10.1073/pnas.1705759114. Epub 2017 Jun 19.Franchi L, Kamada N, Nakamura Y, et al. NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol. 2012 May;13(5):449-56. doi: 10.1038/ni.2263Franchi L, Kamada N, Nakamura Y, et al. NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol. 2012 May;13(5):449-56. doi: 10.1038/ni.2263Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009 Oct 30;139(3):485-98. doi: 10.1016/j.cell.2009.09.033Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009 Oct 30;139(3):485-98. doi: 10.1016/j.cell.2009.09.033Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011 Jan 21;331(6015):337-41. doi: 10.1126/science.1198469. Epub 2010 Dec 23.Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011 Jan 21;331(6015):337-41. doi: 10.1126/science.1198469. Epub 2010 Dec 23.Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 2012 Feb 13;209(2):251-8. doi: 10.1084/jem.20111703. Epub 2012 Jan 30.Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 2012 Feb 13;209(2):251-8. doi: 10.1084/jem.20111703. Epub 2012 Jan 30.Berer K, Boziki M, Krishnamoorthy G. Selective accumulation of pro-inflammatory T cells in the intestine contributes to the resistance to autoimmune demyelinating disease. PLoS One. 2014 Feb 4;9(2):e87876. doi: 10.1371/journal.pone.0087876Berer K, Boziki M, Krishnamoorthy G. Selective accumulation of pro-inflammatory T cells in the intestine contributes to the resistance to autoimmune demyelinating disease. PLoS One. 2014 Feb 4;9(2):e87876. doi: 10.1371/journal.pone.0087876Sano T, Huang W, Hall JA, et al. An IL-23R/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses. Cell. 2015 Oct 8;163(2):381-93. doi: 10.1016/j.cell.2015.08.061. Epub 2015 Sep 24. Erratum in: Cell. 2016 Jan 14;164(1-2):324.Sano T, Huang W, Hall JA, et al. An IL-23R/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses. Cell. 2015 Oct 8;163(2):381-93. doi: 10.1016/j.cell.2015.08.061. Epub 2015 Sep 24. Erratum in: Cell. 2016 Jan 14;164(1-2):324.Tanoue T, Atarashi K, Honda K. Development and maintenance of intestinal regulatory T cells. Nat Rev Immunol. 2016 May;16(5):295-309. doi: 10.1038/nri.2016.36. Epub 2016 Apr 18.Tanoue T, Atarashi K, Honda K. Development and maintenance of intestinal regulatory T cells. Nat Rev Immunol. 2016 May;16(5):295-309. doi: 10.1038/nri.2016.36. Epub 2016 Apr 18.Kim M, Kim CH. Regulation of humoral immunity by gut microbial products. Gut Microbes. 2017 Jul 4;8(4):392-9. doi: 10.1080/19490976.2017.1299311. Epub 2017 Feb 28. Addendum to: Kim M, Qie Y, Park Y, Kim CH. Gut Microbial Metabolites Fuel Host Antibody Responses. Cell Host Microbe. 2016;20(2):202-14.Kim M, Kim CH. Regulation of humoral immunity by gut microbial products. Gut Microbes. 2017 Jul 4;8(4):392-9. doi: 10.1080/19490976.2017.1299311. Epub 2017 Feb 28. Addendum to: Kim M, Qie Y, Park Y, Kim CH. Gut Microbial Metabolites Fuel Host Antibody Responses. Cell Host Microbe. 2016;20(2):202-14.Haase S, Haghikia A, Wilck N, et al. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology. 2018 Jun;154(2):230-8. doi: 10.1111/imm.12933. Epub 2018 Apr 30.Haase S, Haghikia A, Wilck N, et al. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology. 2018 Jun;154(2):230-8. doi: 10.1111/imm.12933. Epub 2018 Apr 30.Camara-Lemarroy CR, Metz L, Meddings JB, et al. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain. 2018 Jul 1;141(7):1900-16. doi: 10.1093/brain/awy131Camara-Lemarroy CR, Metz L, Meddings JB, et al. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain. 2018 Jul 1;141(7):1900-16. doi: 10.1093/brain/awy131Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011 Oct 26;479(7374):538-41. doi: 10.1038/nature10554Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011 Oct 26;479(7374):538-41. doi: 10.1038/nature10554Yokote H, Miyake S, Croxford JL, et al. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol. 2008 Dec;173(6):1714-23. doi: 10.2353/ajpath.2008.080622. Epub 2008 Oct 30.Yokote H, Miyake S, Croxford JL, et al. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol. 2008 Dec;173(6):1714-23. doi: 10.2353/ajpath.2008.080622. Epub 2008 Oct 30.Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013 Aug 8;500(7461):232-6. doi: 10.1038/nature12331. Epub 2013 Jul 10.Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013 Aug 8;500(7461):232-6. doi: 10.1038/nature12331. Epub 2013 Jul 10.Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-24. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-24. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-8. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-8. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.Lavasani S, Dzhambazov B, Nouri M, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010 Feb 2;5(2):e9009. doi: 10.1371/journal.pone.0009009Lavasani S, Dzhambazov B, Nouri M, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010 Feb 2;5(2):e9009. doi: 10.1371/journal.pone.0009009Kwon HK, Kim GC, Kim Y, et al. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin Immunol. 2013 Mar;146(3):21727. doi: 10.1016/j.clim.2013.01.001. Epub 2013 Jan 16.Kwon HK, Kim GC, Kim Y, et al. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin Immunol. 2013 Mar;146(3):21727. doi: 10.1016/j.clim.2013.01.001. Epub 2013 Jan 16.Takata K, Kinoshita M, Okuno T, et al. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. PLoS One. 2011;6(11):e27644. doi: 10.1371/journal.pone.0027644. Epub 2011 Nov 15.Takata K, Kinoshita M, Okuno T, et al. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. PLoS One. 2011;6(11):e27644. doi: 10.1371/journal.pone.0027644. Epub 2011 Nov 15.Rezende RM, Oliveira RP, Medeiros SR, et al. Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. J Autoimmun. 2013 Feb;40:45-57. doi: 10.1016/j.jaut.2012.07.012. Epub 2012 Aug 28.Rezende RM, Oliveira RP, Medeiros SR, et al. Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. J Autoimmun. 2013 Feb;40:45-57. doi: 10.1016/j.jaut.2012.07.012. Epub 2012 Aug 28.Mangalam A, Shahi SK, Luckey D, et al. Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. Cell Rep. 2017 Aug 8;20(6):1269-77. doi: 10.1016/j.celrep.2017.07.031Mangalam A, Shahi SK, Luckey D, et al. Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. Cell Rep. 2017 Aug 8;20(6):1269-77. doi: 10.1016/j.celrep.2017.07.031Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006 Aug;129(Pt 8):1953-71. doi: 10.1093/brain/awl075. Epub 2006 Apr 21.Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006 Aug;129(Pt 8):1953-71. doi: 10.1093/brain/awl075. Epub 2006 Apr 21.Pöllinger B, Krishnamoorthy G, Berer K, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med. 2009 Jun 8;206(6):1303-16. doi: 10.1084/jem.20090299. Epub 2009 Jun 1.Pöllinger B, Krishnamoorthy G, Berer K, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med. 2009 Jun 8;206(6):1303-16. doi: 10.1084/jem.20090299. Epub 2009 Jun 1.Krishnamoorthy G, Wekerle H. EAE: an immunologist's magic eye. Eur J Immunol. 2009 Aug;39(8):2031-5. doi: 10.1002/eji.200939568Krishnamoorthy G, Wekerle H. EAE: an immunologist's magic eye. Eur J Immunol. 2009 Aug;39(8):2031-5. doi: 10.1002/eji.200939568Rumah KR, Linden J, Fischetti VA, Vartanian T. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One. 2013 Oct 16;8(10):e76359. doi: 10.1371/journal.pone.0076359Rumah KR, Linden J, Fischetti VA, Vartanian T. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One. 2013 Oct 16;8(10):e76359. doi: 10.1371/journal.pone.0076359Miyake S, Kim S, Suda W, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One. 2015 Sep 14;10(9):e0137429. doi: 10.1371/journal.pone.0137429Miyake S, Kim S, Suda W, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One. 2015 Sep 14;10(9):e0137429. doi: 10.1371/journal.pone.0137429Tremlett H, Fadrosh DW, Faruqi AA, et al; US Network of Pediatric MS Centers. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol. 2016 Sep 21;16(1):182. doi: 10.1186/s12883-016-0703-3Tremlett H, Fadrosh DW, Faruqi AA, et al; US Network of Pediatric MS Centers. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol. 2016 Sep 21;16(1):182. doi: 10.1186/s12883-016-0703-3Tremlett H, Fadrosh DW, Faruqi AA, et al; US Network of Pediatric MS Centers. Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol. 2016 Aug;23(8):1308-21. doi: 10.1111/ene.13026. Epub 2016 May 13.Tremlett H, Fadrosh DW, Faruqi AA, et al; US Network of Pediatric MS Centers. Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol. 2016 Aug;23(8):1308-21. doi: 10.1111/ene.13026. Epub 2016 May 13.Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016 Jun 28;7:12015. doi: 10.1038/ncomms12015Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016 Jun 28;7:12015. doi: 10.1038/ncomms12015Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016 Jun 27;6:28484. doi: 10.1038/srep28484Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016 Jun 27;6:28484. doi: 10.1038/srep28484Mentis AA, Dardiotis E, Grigoriadis N, et al. Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Mol Neurobiol. 2017 Jul;54(5):3911-23. doi: 10.1007/s12035-0170530-6. Epub 2017 Apr 28.Mentis AA, Dardiotis E, Grigoriadis N, et al. Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Mol Neurobiol. 2017 Jul;54(5):3911-23. doi: 10.1007/s12035-0170530-6. Epub 2017 Apr 28.Mentis AA, Dardiotis E, Grigoriadis N, et al. Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation. Acta Neurol Scand. 2017 Dec;136(6):606-16. doi: 10.1111/ane.12775. Epub 2017 May 23.Mentis AA, Dardiotis E, Grigoriadis N, et al. Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation. Acta Neurol Scand. 2017 Dec;136(6):606-16. doi: 10.1111/ane.12775. Epub 2017 May 23.Кожиева МК, Мельников МВ, Роговский ВС и др. Микробиота кишечника человека и рассеянный склероз. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(10-2):11-9. doi: 10.17116/jnevro201711710211-19Kozhieva MKh, Mel'nikov MV, Rogovsky VS, et al. Gut human microbiota and multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(10-2):11-9. doi: 10.17116/jnevro201711710211-19 (In Russ.)].Mirza A, Forbes JD, Zhu F, et al. The multiple sclerosis gut microbiota: A systematic review. Mult Scler Relat Disord. 2020 Jan;37:101427. doi: 10.1016/j.msard.2019.101427. Epub 2019 Oct 2.Mirza A, Forbes JD, Zhu F, et al. The multiple sclerosis gut microbiota: A systematic review. Mult Scler Relat Disord. 2020 Jan;37:101427. doi: 10.1016/j.msard.2019.101427. Epub 2019 Oct 2.Kozhieva M, Naumova N, Alikina T, et al. Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity. BMC Microbiol. 2019 Dec 30;19(1):309. doi: 10.1186/s12866-0191685-2Kozhieva M, Naumova N, Alikina T, et al. Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity. BMC Microbiol. 2019 Dec 30;19(1):309. doi: 10.1186/s12866-0191685-2Riccio P, Rossano R. Diet, Gut Microbiota, and Vitamins D + A in Multiple Sclerosis. Neurotherapeutics. 2018 Jan;15(1):75-91. doi: 10.1007/s13311-017-0581-4Riccio P, Rossano R. Diet, Gut Microbiota, and Vitamins D + A in Multiple Sclerosis. Neurotherapeutics. 2018 Jan;15(1):75-91. doi: 10.1007/s13311-017-0581-4

The authors declare that there are no conflicts of interest present.